Group | Metastatic | Non- metastatic | ||
---|---|---|---|---|
Total number | BCc1(n = 14) | Placebo (n = 19) | BCc1(n = 12) | Placebo (n = 20) |
(A) Median of overall survival analysis | ||||
Median (days) | 302 | 107 | 482 | 265 |
Std. error | 133.23 | 55.09 | –a | 27.769 |
Median 95% CI (lower) | 40.87 | 0 | –a | 210.573 |
Median 95% CI (upper) | 563.13 | 214.98 | –a | 319.427 |
P-value for test of equality of survival distributions | 0.306 | 0.019 | ||
HRb (BCc1/Placebo) | 0.589 | 0.019 | ||
Stage (n) | ||||
 I | 0 | 0 | 0 | 0 |
 II | 0 | 0 | 0 | 3 |
 III | 0 | 0 | 11 | 10 |
 IIII | 14 | 19 | 0 | 0 |
(B) Death rate analysis | ||||
Death rate (%) | 50 | 53 | 0 | 35 |